Research programme: hepatitis C virus NS3/4A protein inhibitors - AbbVie/Enanta

Drug Profile

Research programme: hepatitis C virus NS3/4A protein inhibitors - AbbVie/Enanta

Alternative Names: EA-058; EA-063; EA-084; HCV serine protease inhibitor programme - Abbott/Enanta

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Enanta Pharmaceuticals
  • Developer AbbVie; Enanta Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Peptide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-C in USA (PO)
  • 23 Mar 2010 Development in this programme is ongoing
  • 26 Apr 2009 Antimicrobial and pharmacokinetics data from preclinical studies in Hepatitis C presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top